Visen Pharmaceuticals is a technology company.
Visen Pharmaceuticals has raised $190.0M across 2 funding rounds.
Visen Pharmaceuticals has raised $190.0M in total across 2 funding rounds.
Visen Pharmaceuticals has raised $190.0M in total across 2 funding rounds.
Visen Pharmaceuticals's investors include Qiming Venture Partners, Vivo Capital.
The premise of your query contains an inaccuracy: Visen Pharmaceuticals is not a technology company—it is a biopharmaceutical company focused on developing and commercializing endocrine disease treatments.
Visen Pharmaceuticals is an innovative biopharmaceutical company committed to treating endocrine-related diseases.[2][4] Rather than building software or technology products, Visen develops pharmaceutical therapies licensed from its parent company, Ascendis Pharma, specifically tailored for the greater China market. The company serves patients suffering from endocrine disorders and aims to bring FDA-approved and European-approved medicines to Chinese patients who currently lack access to these treatments. Visen's growth momentum has been significant: the company raised approximately $190 million in funding before its public market debut, including a $150 million Series B round in early 2021.[1]
Visen Pharmaceuticals was formed in 2018 by Ascendis Pharma and an investor syndicate led by Vivo Capital.[1] The company was created as a strategic spinout to develop and commercialize Ascendis' endocrinology pipeline specifically for the greater China region. Leadership is headed by CEO Pony Lu, who previously served as president of Takeda's China unit and held leadership roles at Servier's Taiwan, China, and France operations, as well as at AstraZeneca Taiwan.[1] This experienced management team brought deep pharmaceutical industry expertise and regional market knowledge to the venture.
Visen exemplifies a growing trend of specialized biotech spinouts focused on geographic market expansion. Rather than competing globally, Visen leverages a parent company's R&D investments while focusing exclusively on a high-growth market with significant unmet medical needs. This model allows Ascendis to expand its market reach while maintaining focused operations. The timing is favorable: China's healthcare system is increasingly willing to approve innovative therapies, and endocrine diseases represent a substantial patient population with limited treatment options. Visen's success influences the broader ecosystem by demonstrating that specialized regional biotech ventures can attract institutional capital and achieve public market exits.
Visen is positioned to capture significant value by bringing world-class endocrine therapies to a market of over 1.4 billion people with limited access to these treatments. The company's near-term focus is obtaining Chinese regulatory approval for its lead assets, particularly the pediatric growth hormone deficiency drug already approved by the FDA.[1] Long-term, Visen may expand its pipeline beyond Ascendis-licensed assets or explore additional partnerships. The company's success will largely depend on navigating Chinese regulatory timelines and building market awareness among physicians and patients—challenges distinct from those faced by global biotech firms.
Visen Pharmaceuticals has raised $190.0M across 2 funding rounds. Most recently, it raised $150.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $150.0M Series B | Qiming Venture Partners, Vivo Capital | |
| Nov 1, 2018 | $40.0M Series A | Qiming Venture Partners, Vivo Capital |